Group 1 - The company announced that Mr. Shi Yongjin will resign as an independent non-executive director effective September 30, 2025, and will no longer serve as the chairman of the audit committee [1] - Mr. Yu Haoming has been appointed as an independent non-executive director and a member of the audit committee [1] - Mr. Li Guodong has been appointed as the chairman of the audit committee [1]

Core Viewpoint - Fosun Pharma (01652.HK) announced significant changes in its board of directors and audit committee effective September 30, 2025 [1] Group 1 - Shi Yongjin has resigned as an independent non-executive director and will no longer serve as the chairman of the audit committee [1] - Yu Haoming has been appointed as an independent non-executive director and a member of the audit committee [1] - Li Guodong has been appointed as the chairman of the audit committee [1]

Fusen Pharmaceutical Company Limited 福 森 藥 業 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1652） 獨立非執行董事 余浩銘，李國棟，杜潔華 董事會設立3個委員會。下表提供各董事會成員在這些委員會中所擔任的職位。 | | 委員會 | | | | | --- | --- | --- | --- | --- | | 董事會 | | 審核委員會 | 提名委員會 | 薪酬委員會 | | 侯太生 | | | | | | 遲永勝 | | | | | | 孟慶芬 | | | | | | 曹智銘 | | | 主席 | 成員 | | 余浩銘 | | 成員 | | | | 李國棟 | | 主席 | 成員 | 主席 | | 杜潔華 | | 成員 | 成員 | 成員 | 董事名單與其角色和職能 本公司董事（「董事」）會（「董事會」）成員載列如下。 董事會主席及執行董事 曹智銘 執行董事 侯太生，遲永勝，孟慶芬 香港，2025年9月30日 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Fusen Pharmaceutical Company Limited 福 森 藥 業 有 限 公 司 董事會謹此宣佈以下變更，自2025年9月30日起生效： 福 森 藥 業 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事（「 董 事 」）會 （「董事會」）謹此宣佈以下變更，自2025年9月30日起生效。 獨立非執行董事辭任 施永進先生（「施先生」）已提請辭任獨 立非執行董事，自2025 年9月30 日起生效， 以 便 投 入 更 多 時 間 處 理 其 他 事 務 。 施 先 生 已 確 認 ， 彼 與 董 事 會 之 間 並 無 意 見 分 歧 ， 亦 無 有 關 彼 辭 任 獨 立 非 執 行 董 事 之 其 他 事 宜 須 促 請 本 公 司 股 東（「 股 東 」）或 香港聯 ...

Fusen Pharmaceutical Company Limited 福森藥業有限公司 (Incorporated in the Cayman Islands with limited liability) ( 於開曼群島註冊成立的有限公司 ) (Stock Code 股份代號：1652) N O T I F I C AT I O N L E T T E R 29 September 2025 Dear Non-registered holders(Note 1) Fusen Pharmaceutical Company Limited (the "Company") – Notice of Publication of Interim Report 2025 (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese languages and are available on the webs ...

Fusen Pharmaceutical Company Limited 福森藥業有限公司 Fusen Pharmaceutical Company Limited (the "Company") – Notice of Publication of Interim Report 2025 (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese languages and are available on the website of The Stock Exchange of Hong Kong Limited ("HKEX") at www.hkexnews.hk and the Company's website at www.fusenpharma.com. If you have any difficulty in receiving or gaining access to the C ...

Financial Performance - The company's operating revenue for the first half of 2025 was approximately RMB 111.3 million, a decrease of about 43.3% compared to RMB 196.3 million in the same period of 2024[7] - The net loss attributable to shareholders for the first half of 2025 was approximately RMB 23.1 million, a reduction of about 37.4% from a net loss of RMB 36.9 million in the same period of 2024[7] - The total revenue for the first half of 2025 decreased by approximately 43.3% to RMB 111.3 million from RMB 196.3 million in the first half of 2024, primarily due to weak market demand[10] - The gross profit for the same period was RMB 42,990,000, down 59.3% from RMB 105,872,000 in 2024[60] - The company experienced a total comprehensive loss of RMB 23,121,000 for the six months ended June 30, 2025, compared to a loss of RMB 36,941,000 for the same period in 2024, showing an improvement of approximately 37.4%[64] - The group reported a significant revenue decline, with total revenue for the six months ended June 30, 2025, at RMB 111,286,000, down 42% from RMB 192,064,000 in the same period of 2024[76] - The group experienced a pre-tax loss of RMB 23,136,000 for the six months ended June 30, 2025, compared to a loss of RMB 36,941,000 for the same period in 2024[83] Product Sales - The sales revenue from the core product, Shuanghuanglian Oral Liquid, decreased by approximately 33.1% to RMB 56.1 million in the first half of 2025 from RMB 83.9 million in the same period of 2024[11] - The sales revenue from Shuanghuanglian Injection decreased by approximately 70.5% to RMB 16.2 million in the first half of 2025 from RMB 54.8 million in the same period of 2024[11] Expenses and Cost Management - Sales and distribution expenses for the first half of 2025 reached approximately RMB 30.6 million, accounting for about 27.5% of revenue, a decrease consistent with the revenue decline[14] - General and administrative expenses significantly decreased from approximately RMB 36.2 million in the first half of 2024 to about RMB 14.7 million in the first half of 2025, primarily due to reduced credit losses on trade and other receivables[15] - R&D expenses in the first half of 2025 were approximately RMB 14.9 million, a decrease of about RMB 42.2 million from RMB 57.1 million in the first half of 2024, mainly due to reduced investment in non-core product projects[16] Joint Ventures and Investments - The joint venture, Jiangxi Yongfeng Kande Pharmaceutical Co., Ltd., reported a profit of approximately RMB 26.3 million in the first half of 2025, with a profit attributable to the company of RMB 9.4 million, a significant improvement from a loss of RMB 0.36 million in the same period of 2024[7] - The group received government grants totaling RMB 1,192,000 for the six months ended June 30, 2025, down from RMB 3,976,000 in 2024[78] Cash Flow and Liquidity - The company reported a net cash position of RMB 75,988,000 as of June 30, 2025, significantly up from RMB 21,056,000 at the end of 2024[62] - The company reported a net cash inflow from operating activities of RMB 31,058,000 for the six months ended June 30, 2025, compared to RMB 33,837,000 for the same period in 2024, reflecting a decrease of about 8.2%[66] - The company made significant investments, with net cash used in investing activities amounting to RMB 22,119,000 for the six months ended June 30, 2025, compared to a cash outflow of RMB 83,534,000 in the same period of 2024[66] Liabilities and Equity - As of June 30, 2025, the group's total liabilities amounted to approximately RMB 887.4 million, an increase from RMB 869.8 million as of December 31, 2024[23] - The asset-liability ratio increased from 103.9% as of December 31, 2024, to 105.4% as of June 30, 2025[26] - The company's total equity attributable to shareholders decreased to RMB 346,550,000 as of June 30, 2025, from RMB 369,671,000 as of December 31, 2024, reflecting a decline of about 6.3%[64] Stock Options and Share Plans - The company has 16,000,000 unexercised stock options under the stock option plan, equivalent to approximately 2.16% of the total issued share capital[39] - The total number of stock options available for grant as of January 1, 2025, and June 30, 2025, is 64,000,000 shares, which corresponds to about 8.66% of the total issued share capital[39] - The board proposed to extend the exercise period of unexercised stock options to a maximum of 10 years from the grant date, enhancing alignment with shareholder interests[39] - The Restricted Share Unit Plan was adopted on November 8, 2021, aimed at incentivizing qualified individuals to contribute to the group's future development and expansion[42] - The maximum number of restricted share units (RSUs) that can be granted under the plan is capped at 10% of the company's issued share capital as of the adoption date, equating to 76,993,400 shares[44] Corporate Governance - The company has adhered to all applicable corporate governance codes, except for specific provisions regarding the separation of roles between the chairman and CEO[50] - The board has the discretion to determine eligibility for RSU grants based on contributions to the company's growth[43] Employee and Workforce - The group had a total of 1,045 employees as of June 30, 2025, with total employee costs amounting to approximately RMB 31.0 million in the first half of 2025, down from RMB 41.4 million in the same period of 2024[29] Market Outlook - The company is cautiously optimistic about the operating performance for the second half of 2025, expecting gradual improvement in revenue and gross margin as the impact of the national centralized procurement becomes evident[9] - The company is focused on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the report[67]

Group 1 - Fosun Pharmaceutical (001288) announced the sale of its wholly-owned subsidiary, Henan Fosun Smart Energy Technology Co., Ltd., for 73 million yuan to Henan Xisheng Industrial Development Co., Ltd. [1] - The buyer, Henan Xisheng, is jointly controlled by Nanyang Industrial Investment Group (51% stake) and the Xichuan Finance Bureau (49% stake), focusing on property leasing, equipment leasing, and overseas engineering contracting [3]. - The subsidiary, Fosun Smart Energy, primarily operates photovoltaic power generation systems, with three installed capacities of approximately 6.09 MW, 6.38 MW, and 14.89 MW [3]. Group 2 - Fosun Pharmaceutical stated that its core business is pharmaceutical manufacturing and sales, and the photovoltaic business was initially intended to support internal power needs and generate external revenue, but it is not a core focus of the group [3]. - The sale aligns with the company's long-term strategy to streamline operations and focus on key business areas, and it will not significantly impact the company's daily pharmaceutical production and operations [3].

Core Viewpoint - Fosun Pharma (1652.HK) announced the sale of its wholly-owned subsidiary, Fosun Smart Energy Technology Co., Ltd., for 73 million yuan to Henan Xisheng Industrial Development Co., Ltd. This strategic move aims to streamline resources and refocus on its core pharmaceutical business [1][4]. Group 1: Transaction Details - The buyer, Henan Xisheng, is primarily engaged in property leasing and management, equipment leasing, enterprise engineering, and private equity investment [4]. - Fosun Smart Energy was established in February 2023 with a registered capital of 50 million yuan, focusing on the installation and operation of photovoltaic power generation systems [4]. - The sale price of 73 million yuan is expected to yield a profit of 1.3 million yuan for Fosun Pharma, with net proceeds of approximately 72.8 million yuan allocated for general working capital [4]. Group 2: Business Context - Fosun Smart Energy operates three photovoltaic systems with installed capacities of approximately 6.089 MW, 6.387 MW, and 14.886 MW [4]. - The photovoltaic business is not a core focus for Fosun Pharma, which is primarily centered on its pharmaceutical operations [4]. - The company has been experiencing losses since 2022, with net losses of 34.61 million yuan in 2022, 36.28 million yuan in 2023, and an expected loss of 189 million yuan in 2024 [5]. Group 3: Recent Developments - On September 15, Fosun Pharma received approval for its Metformin and Ertugliflozin tablets, which are intended to improve blood sugar control in adults with type 2 diabetes [5]. - Following this approval, the company's stock price surged over 400% on September 16, reaching a new high for 2023 [5]. - The approval of this product, although a generic drug, has bolstered Fosun Pharma's confidence in its core pharmaceutical business and may have influenced the decision to divest from non-core operations [5].

Major Events - Different Group (06090) has a public offering with a subscription rate of 3317.47 times the upper limit price [1] - Botai Che Lian (02889) plans to globally offer 10.4369 million H-shares from September 22 to September 25 [1] - Changhong Jiahua (03991) received a privatization offer from Changhong Group at a premium of approximately 32.93%, with resumption of trading on September 23 [1] - Huajian Medical (01931) signed a strategic cooperation agreement with Chuangsheng Group-B (06628) involving the tokenization of a $1.5 billion innovative drug pipeline asset [1] - Gilead Sciences-B (01672) reported that ASC47 combined with Semaglutide showed a weight loss effect improvement of up to 56.2% compared to Semaglutide alone in obese subjects [1] - Fosen Pharmaceutical (01652) plans to sell all equity of Henan Fosen Smart Energy Technology for 73 million yuan [1] - Maiyue Technology (02501) entered into strategic cooperation agreements with NetEase Youdao and Ferry International [1] - Zhongchuang Zhiling (00564) intends to invest 270 million yuan to establish Yaxinke Thermal Management Technology (Yizheng) Co., Ltd. to enhance market competitiveness in automotive thermal management systems [1] - Garmin Group Holdings (01271) plans to sell a portfolio of four data center projects for 5.25 billion HKD [1] Buybacks and Increases - Tencent Holdings (00700) repurchased 862,000 shares for 550 million HKD on September 22 [1] - Standard Chartered Group (02888) repurchased 517,100 shares for 7.3877 million GBP on September 19 [1] - Midea Group (00300) repurchased 3.415 million A-shares for 250 million yuan on September 22 [1] - Anta Sports (02020) repurchased 2.12 million shares for 199 million HKD on September 22 [1] - Kuaishou-W (01024) repurchased 1 million shares for 73.7998 million HKD on September 22 [1] - Heng Rui Pharmaceutical (01276) repurchased 656,000 A-shares for 45.7493 million yuan on September 19 [1] - Shenzhen Expressway Company (00548) received an increase of 25.38 million H-shares from shareholder Yunsong Capital [1]